BRAF and in situ carcinoma: Considering that the co-expression of LOXL3, SNAI1, and NES in melanoma has not been described in the existing literature, our study aimed to determine whether LOXL3, SNAI1, and NES are potential risk factors and whether their expression can be used to predict melanoma progression and metastasis in patients with dysplastic nevi, melanoma in situ, and BRAF+ and BRAF− metastatic melanoma.